Analyst Price Targets — PGNY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 10:24 am | Jailendra Singh | Truist Financial | $28.00 | $17.69 | StreetInsider | Progyny (PGNY) PT Lowered to $28 at Truist Securities |
| January 21, 2026 12:17 pm | — | J.P. Morgan | $35.00 | $25.28 | TheFly | Progyny price target raised to $35 from $30 at BTIG |
| January 8, 2026 2:24 pm | Jailendra Singh | Truist Financial | $34.00 | $28.23 | TheFly | Progyny upgraded to Buy from Hold at Truist |
| January 8, 2026 12:44 pm | Scott Schoenhaus | KeyBanc | $32.00 | $26.80 | TheFly | Progyny price target raised to $32 from $30 at KeyBanc |
| December 8, 2025 9:16 pm | Peter Warendorf | Barclays | $29.00 | $24.70 | TheFly | Progyny initiated with an Overweight at Barclays |
| November 11, 2025 9:42 pm | — | KeyBanc | $30.00 | $23.81 | TheFly | KeyBanc upgrades Progyny to Overweight on 'emerging' catalysts |
| August 8, 2025 2:17 pm | Sarah James | Raymond James | $28.00 | $22.22 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Progyny (PGNY) |
| July 17, 2025 12:42 pm | Jailendra Singh | Truist Financial | $27.00 | $23.05 | TheFly | Progyny price target raised to $27 from $24 at Truist |
| February 28, 2025 11:38 am | — | Canaccord Genuity | $23.00 | $22.53 | TheFly | Progyny price target raised to $23 from $17 at Canaccord |
| November 13, 2024 6:59 pm | Glen Santangelo | Jefferies | $19.00 | $21.61 | StreetInsider | Progyny (PGNY) PT Lowered to $19 at Jefferies |
Latest News for PGNY
Progyny (PGNY) is undervalued at 9.3x forward P/E, with strong cash flow, expanding margins, and a resilient business model post-Amazon client loss. Headline FY26 growth appears muted (5.1%–9%) due to tough comps, but underlying growth excluding Amazon is 9.3–13.3%, with stable utilization rates near 1% and covered lives still expanding. PGNY's differentiated, outcome-focused platform, high retention, and buybacks…
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.42 per share a year ago.
The headline numbers for Progyny (PGNY) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PGNY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.